cyclosporine vs ledipasvir/sofosbuvir
According to this portal's Publishing Organization, this page was last reviewed in August 2026 against our methodology. Figures and extracts on this site, including tables above 1,000 rows when the corpus is that large, are the publisher's responsibility.
Side-by-side comparison of cyclosporine and ledipasvir/sofosbuvir. Data from FDA drug databases (Orange Book, NDC Directory, recalls, shortages) covering 20,000+ approved drugs, plus CMS pricing; see our methodology.
minor Known Drug Interaction
7.3 Drugs without Clinically Significant Interactions with HARVONI Based on drug interaction studies conducted with the components of HARVONI (ledipasvir or sofosbuvir) or HARVONI, no clinically significant drug interactions have been either observed or are expected when HARVONI is used with the following drugs [see Clinical Pharmacology (12.3) ]: abacavir, atazanavir/ritonavir, cyclosporine, darunavir/ritonavir, dolutegravir, efavirenz, elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide, emtricitabine, lamivudine, methadone, midazolam, oral contraceptives, pravastatin,...
Neoral, Sandimmune, Restasis
Harvoni
Vevye eye drops contain cyclosporine. They help treat the signs and symptoms of dry eye disease.
Harvoni is a medicine that contains ledipasvir and sofosbuvir. It is used to treat chronic hepatitis C virus (HCV) infection in adults and children 3 years and older.
Vevye treats the signs and symptoms of dry eye disease. Dry eye can cause discomfort, stinging, and blurred vision. This medicine can help reduce these symptoms.
Harvoni treats chronic Hepatitis C virus (HCV) genotypes 1, 4, 5, or 6. It can be used if you don't have cirrhosis or if you have compensated cirrhosis. If you have genotype 1 with decompensated cirrhosis or are a liver transplant recipient with genotype 1 or 4, you will take Harvoni with another medicine called ribavirin.
Vevye contains cyclosporine, which is an immunosuppressant. It works by decreasing inflammation in the eyes. This helps your eyes make more tears.
Harvoni contains two medicines that stop the hepatitis C virus from multiplying in your body. Ledipasvir blocks a protein called NS5A. Sofosbuvir blocks another protein called NS5B.
- • Irritation where the drops are applied (8%)
- • Feeling tired
- • Headache
- • Feeling weak
- • Nausea
- Eye Irritation 7,786
- Pyrexia 4,064
- Eye Pain 3,808
- Nausea 3,623
- Diarrhoea 3,562
- Feeling tired 4,130
- Headache 3,706
- Nausea 1,240
- Diarrhea 913
- Hepatitis C 883
To avoid eye injury or contamination, do not touch the bottle tip to your eye or any other surface. Do not use Vevye while wearing contact lenses. If you wear contacts, remove them before using the drops. You can put them back in 15 minutes after using Vevye.
Harvoni can cause Hepatitis B to become active again if you have had it in the past. This can cause serious liver problems, including liver failure and death. Your doctor will test you for Hepatitis B before you start Harvoni and monitor you during and after treatment.
It is not known if Vevye will harm an unborn baby. Talk to your doctor if you are pregnant or plan to become pregnant. Cyclosporine can pass into breast milk after being taken orally, but it is unknown if it passes into breast milk from eye drops. Talk to your doctor if you are breastfeeding.
If you are pregnant or plan to become pregnant, talk to your doctor before taking Harvoni. If Harvoni is taken with ribavirin, it is unsafe during pregnancy. Talk to your doctor if you are breastfeeding or plan to breastfeed.
How to Read This cyclosporine vs ledipasvir/sofosbuvir Comparison
cyclosporine is classified in the Calcineurin Inhibitor (Immunosuppressant) drug class, while ledipasvir/sofosbuvir sits within the NS5A/NS5B Inhibitor (HCV) class. Drugs from different classes work through distinct mechanisms, so a head-to-head comparison illustrates trade-offs rather than equivalence. Both drugs are prescription-only, so a licensed provider must authorize use.
Adverse event totals above are pulled from the FDA's Adverse Event Reporting System (FAERS). For these top-ranked reactions alone, cyclosporine has 22,843 submissions while ledipasvir/sofosbuvir has 10,872. Those figures reflect cumulative reporting volume, not per-patient risk, so older, widely dispensed drugs typically look worse on count alone. These two drugs have a known minor interaction flagged in FDA labeling, attributed to these medications do not change how the other drug works or how much of it stays in your body.. Serious warnings, pregnancy guidance, and contraindications can differ even when indications overlap.
A table cannot represent individual circumstances. Data here is sourced from FDA Structured Product Labels (SPL) and FAERS, both of which update as manufacturers and clinicians submit new information. This registry does not provide medical, treatment, substitution, or medication-change directions for cyclosporine or ledipasvir/sofosbuvir.
Registry boundary: This comparison displays source-record fields and does not provide individualized medical direction.